Abstract
Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.
| Original language | English (US) |
|---|---|
| Pages | 41-44 |
| Number of pages | 4 |
| Volume | 41 |
| No | 8 |
| Specialist publication | U.S. Pharmacist |
| State | Published - Aug 1 2016 |
All Science Journal Classification (ASJC) codes
- Pharmacy
- Pharmacology
- Pharmaceutical Science
Fingerprint Dive into the research topics of 'Gonorrhea: Treatment and management considerations for the male patient'. Together they form a unique fingerprint.
Cite this
Dalke, B., Ivers, T., O’Brien, K. K., Castillo, S., Hoie, E., & Begley, K. J. (2016). Gonorrhea: Treatment and management considerations for the male patient. U.S. Pharmacist, 41(8), 41-44.